2-4-羧苯基四甲基咪唑烷-1-氧-3-氧化物
2-4-羧苯基四甲基咪唑烷-1-氧-3-氧化物 性质
| 熔点 | 141-143°C |
|---|---|
| 储存条件 | 2-8°C |
| 溶解度 | H2O: >20 mg/mL |
| 形态 | 固体 |
| 颜色 | 蓝色的 |
| 水溶解性 | Soluble in water. Also soluble in ethanol, methanol, DMSO or DMF. |
| 稳定性 | 供货时可稳定保存 2 年。 DMSO 或蒸馏水中的溶液可在 -20°C 下保存长达 1 个月。 |
| CAS 数据库 | 148819-94-7(CAS DataBase Reference) |
2-4-羧苯基四甲基咪唑烷-1-氧-3-氧化物 用途与合成方法
Carboxy-PTIO potassium (200 μM; 1 h prior to physalin A; 24 hours) significantly suppresses the stimulation of NO expression induced by physalin A treatment, but no change is observed in Carboxy-PTIO treatment alone.Carboxy-PTIO potassium (200 μM; 1 h prior to physalin A; 24 hours) reduces physalin A-induced cleavage of procaspase-3 and PARP, down-regulated ICAD expression,diminishing DNA fragmentation in nuclei.Carboxy-PTIO potassium (200 μM; 1 h prior to physalin A; 24 hours) shows no effect on iNOS expression. However, decreased-mTOR and p-mTOR levels induced by physalin A is reversed by Carboxy-PTIO with concomitant suppression of LC3 I to LC3 II conversions in A375-S2 cells .
Western Blot Analysis
| Cell Line: | A375-S2 cells |
| Concentration: | 200 μM |
| Incubation Time: | 1 h prior to physalin A; 24 hours |
| Result: | Diminished physalin A-induced procaspase-3 and PARP cleavage. |
Carboxy-PTIO (intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min) treatment improves the hypotension, renal dysfunction and survival rate in Lps-treated rats. But it does not affect each parameter in naomal rats.
| Animal Model: | SD rats |
| Dosage: | 0.056-1.70 mg/kg/min |
| Administration: | Intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min |
| Result: | Exhibited a potent therapeutic value in endotoxin shock through the direct scavenging action against NO. |
